

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

INSIDE INFORMATION; DELAY IN PUBLICATION OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021; AND FURTHER DELAY IN DESPATCH OF CIRCULAR

This announcement is made by Link-Asia International MedTech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

DELAY IN PUBLICATION OF ANNUAL RESULTS

The board (“**Board**”) of directors of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) that there will be a delay in the release of the annual results for the year ended 31 December 2021 (the “**2021 Annual Results**”). The main reason the Company’s auditing process for the year ended 31 December 2021 has been disrupted due to the implementation of the COVID-19 pandemic prevention and control quarantine measures in certain cities in the PRC. Such arrangements included allowing Shenzhen office staffs, Hong Kong office staffs and auditors to take turns to work from home. It is currently expected that the Company will not be in a position to publish the audited 2021 Annual Results announcement on or before 31 March 2022.

Pursuant to Rules 13.49(1) of the Listing Rules, the Company is required to publish the 2021 Annual Results on or before 31 March 2022. The delay in publication of the 2021 Annual Results constitutes non-compliance of Rules 13.49(1) of the Listing Rules.

Discussions with the auditors are ongoing and the Board and the management of the Company are doing their utmost to assist and cooperate with the auditors so that the 2021 Annual Results and 2021 annual report are expected to be published by the end of April

2022. Notwithstanding the delay in publication of the 2021 Annual Results, the Board wishes to emphasize that the operation of the Company and its subsidiaries remain normal and that it will continue to work with the auditors closely with a view to publish the 2021 Annual Results as soon as possible.

PUBLICATION OF UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results, it must announce its results based on the financial results which have yet to be agreed with the auditor (so far as the information is available). In order to keep the Shareholders and potential investors informed of the Group's business operations and financial position, the Board will review and approve, among other things, the publication of the unaudited annual results of the Company for the year ended 31 December 2021 (the **"2021 Unaudited Annual Results"**) on 30 March 2022. The Company will publish further announcement in relation to the 2021 Unaudited Annual Results as and when appropriate.

FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to (i) the announcement of dated 18 January 2022 in relation to the Assignment of Agency Agreement involving the issue of Consideration Shares under Specific Mandate and (ii) the announcements of the Company dated 9 February 2022 and 4 March 2022 in relation to the delay in despatch of circular (the **"Announcements"**). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, a circular (the **"Circular"**) containing, among other information, (i) details of the Assignment; (ii) details of the Specific Mandate; and (iii) a notice convening the EGM together with a form of proxy for use at the EGM was expected to be despatched to the Shareholders on or before 25 March 2022. As additional time is required for the Company to finalise certain information to be included in the Circular, the Company expects that the date of despatch of the Circular will be postponed to a date falling on or before 15 April 2022.

FURTHER ANNOUNCEMENT(S)

The Company will publish further announcement(s) to inform Shareholders and potential investors any material developments in connection with the above matters as and when appropriate.

By order of the Board
Link-Asia International MedTech Group Limited
Lin Dailian
Chairman and executive Director

Hong Kong, 25 March 2022

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.